Frontlight ResearchEarly access
Taking peoplePhase 4
STRAtified Dosing based on Augmented renal clearance for CEFtriaxone in patients with severe community-acquired pneumonia: the STRADA-CEF trial
Key facts
- Who runs it
- UZ Leuven
- Where
- Belgium6 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 270 people, planned
- Started
- 18 Mar 2024
- Expected to end
- 7 Apr 2027
- Type of study
- Interventional
- Record updated
- 10 August 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to – or within 72 hours after oral consent prior to – any screening procedures
- Use of highly effective methods of birth control; defined as those that, alone or in combination, result in low failure rate (i.e., less than 1% per year) when used consistently and correctly; such as implants, injectables, combined oral contraceptives, some IUDs, true sexual abstinence (i.e. refraining from heterosexual intercourse during the entire period of risk associated with the Trial treatment(s)) or commitment to a vasectomised partner
- Aged 18 years or older at the baseline visit
- Confirmed diagnosis of sCAP, as defined by the current IDSA/ATS guideline
- Ceftriaxone initiated for sCAP
- (Planned) admission to an ICU ward
Who cannot take part
- Need for renal replacement therapy on the day of inclusion
- Patients with (suspicion of) meningitis, requiring treatment with ceftriaxone 2g q12h
- Patients having received more than 1 amoxicillin-clavulanate dose since hospital admission
- Patients expected to stop ceftriaxone therapy within 48h
- Patients receiving palliative treatment under a “discontinue therapy" code
- Previous enrolment in this study
- Any prior or concomitant treatment(s) that might jeopardise the participant’s safety or that would compromise the integrity of the Trial
- Mildly to moderately decreased eGFRCKD-EPI (<80 mL/min/1.73m²) at baseline (max. 1 year prior to hospital admission)
- Any disorder, which in the Investigator’s opinion might jeopardise the participant’s safety or compliance with the protocol
- Known hypersensitivity to beta-lactam antibiotics
- Ceftriaxone treatment >12h before study enrolment
- Patients expected to be discharged from the ICU within 48h
- Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate, highly effective contraceptive. A woman is considered of child-bearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause
- Participation in an interventional Trial with an investigational medicinal product (IMP) or device
This trial is currently available in Belgium.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The general objective of this project is to evaluate the clinical benefit and safety of stratified every 24-hour (q24h) vs. q12h 2g ceftriaxone therapy in critically ill patients with sCAP based on the risk for development of ARC.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 10 August 2026